May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Glycodelin: A Novel Serum Anti–Inflammatory Marker in Type 1 Diabetic Retinopathy During Pregnancy
Author Affiliations & Notes
  • S. Loukovaara
    Helsinki University Central Hospital, Helsinki, Finland
    Ophthalmology,
  • I.R. J. Immonen
    Helsinki University Central Hospital, Helsinki, Finland
    Ophthalmology,
  • M.J. Loukovaara
    Helsinki University Central Hospital, Helsinki, Finland
    Obstetrics and Gynaecology,
  • R. Koistinen
    Helsinki University Central Hospital, Helsinki, Finland
    Obstetrics and Gynaecology,
  • R.J. Kaaja
    Helsinki University Central Hospital, Helsinki, Finland
    Obstetrics and Gynaecology,
  • Footnotes
    Commercial Relationships  S. Loukovaara, None; I.R.J. Immonen, None; M.J. Loukovaara, None; R. Koistinen, None; R.J. Kaaja, None.
  • Footnotes
    Support  Academy of Finland, the Finnish Eye Foundation, the Foundation for Diabetes Research
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1010. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Loukovaara, I.R. J. Immonen, M.J. Loukovaara, R. Koistinen, R.J. Kaaja; Glycodelin: A Novel Serum Anti–Inflammatory Marker in Type 1 Diabetic Retinopathy During Pregnancy . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1010.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Inflammation may play an important role in the development of diabetic retinopathy during pregnancy. Glycodelin is a glycoprotein whose secretion from endometrial glands increases during pregnancy. Glycodelin may protect against inflammatory tissue damage. We studied role of glycodelin in the development and progression of retinopathy in type 1 diabetes during pregnancy.

Methods: : Retinopathy was graded from fundus photographs in 45 diabetic and in 9 nondiabetic women prospectively during pregnancy. Serum glycodelin concentration was measured by an immunofluorometric assay.

Results: : In diabetic women with progression of retinopathy, glycodelin concentration was 263 [116–505] ng/ml during the first trimester, 61 [30–106] ng/ml during the second trimester, and 29 [13–53] ng/ml during the third trimester, compared with values of 595 [376–870], 104 [75–228] and 45 [32–74], respectively, in diabetics without progression (P = 0.005 between the groups). Low glycodelin concentration was associated with progression of diabetic retinopathy in multiple regression analysis. Serum glycodelin concentration was similar in diabetic and nondiabetic women throughout pregnancy (P = 0.63 by repeated measures ANOVA).

Conclusions: : Diabetes per se is not associated with altered serum glycodelin concentration during pregnancy. Low glycodelin concentration is associated with progression of retinopathy in pregnant diabetic women. Data suggest that low glycodelin concentration may be insufficient to suppress inflammatory protein levels of cytokines and adhesion molecules known to be associated with retinopathy progression.

Keywords: diabetic retinopathy • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×